{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:58:22Z","timestamp":1780574302384,"version":"3.54.1"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> In last 2\u00a0decades, there have been substantial changes in the utilization patterns of antihypertensive medicines following new clinical trials and the introduction of new treatment guidelines. The aim of this study was to analyze utilization and prescribing patterns regarding antihypertensive medicines in the Republic of Srpska, Bosnia and Herzegovina during an 11-years follow-up according to national and European treatment guidelines.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In this retrospective, observational study, medicine utilization data were analyzed between 2009\u20132019 period using the ATC\/DDD methodology and expressed as the number of DDD\/1,000 inhabitants\/day (DID\/TID). The medicine utilization 90% (DU90%) method was used for determine the quality of prescribing.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> During the observed period, the use of antihypertensive medicines increased more than 3-times (125.97 DDD\/TID in 2009 vs 414.95 DDD\/TID in 2019), corresponding to a rise in the prevalence of hypertensive patients from 91.7\/1,000 to 186.3\/1,000 in the same period. This was mainly driven by increased use of angiotensin converting enzyme inhibitors with 241.69%, beta blockers with 146.87%, calcium channel blockers with 251.55%, and diuretics with 178.95%. Angiotensin receptor blockers were the fastest growing group of antihypertensive medicines in this period and their utilization increased nearly 40 times.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> The overall antihypertensive medicines utilization was largely influenced by national and ESH\/ESC guidelines and strongly corresponded to the positive medicine list of the national health insurance fund. Antihypertensive medicines utilization is comparable with medicine utilization trends in other countries.<\/jats:p>","DOI":"10.3389\/fphar.2022.889047","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T05:50:45Z","timestamp":1655272245000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up"],"prefix":"10.3389","volume":"13","author":[{"given":"Dragan","family":"Kalini\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranko","family":"\u0160krbi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161ko","family":"Vuli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a","family":"Stojakovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svjetlana","family":"Stoisavljevi\u0107-\u0160atara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo\u0161 P.","family":"Stojiljkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Markovi\u0107-Pekovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Goli\u0107 Jeli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a","family":"Pilipovi\u0107-Bro\u0107eta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Godman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jash.2007.04.005","article-title":"A Specific Training on Hypertension Guidelines Improves Blood Pressure Control by More Than 10% in Hypertensive Patients: the VALNORM Study","volume":"1","author":"Asmar","year":"2007","journal-title":"J. Am. Soc. Hypertens."},{"key":"B2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11906-020-01069-7","article-title":"Low-Dose Combination Therapy for Initial Treatment of Hypertension","volume":"22","author":"Atkins","year":"2020","journal-title":"Curr. Hypertens. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1161\/CIRCRESAHA.119.315270","article-title":"Response by Benetos et al to Letter Regarding Article, \"Hypertension Management in Older and Frail Older Patients\"","volume":"125","author":"Benetos","year":"2019","journal-title":"Circ. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(19)31629-0","article-title":"Fixed-dose Combination Antihypertensive Medications","volume":"394","author":"Benjamin","year":"2019","journal-title":"Lancet"},{"key":"B5","first-page":"7","article-title":"Are Prescribing Initiatives Readily Transferable across Classes: the Case of Generic Losartan in Scotland?","volume":"21","author":"Bennie","year":"2013","journal-title":"Qual. Prim. Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s002280050431","article-title":"Drug Utilization 90%--a Simple Method for Assessing the Quality of Drug Prescribing","volume":"54","author":"Bergman","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijcard.2016.05.044","article-title":"Lack of Control of Hypertension in Primary Cardiovascular Disease Prevention in Europe: Results from the EURIKA Study","volume":"218","author":"Borghi","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1080\/14740338.2020.1836151","article-title":"Safety Implications of Combining ACE Inhibitors with Thiazides for the Treatment of Hypertensive Patients","volume":"19","author":"Borghi","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial against Atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of Cardiovascular Events with an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(05)74355-5","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A Randomised Trial","volume":"353","author":"Dargie","year":"1999","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.18203\/2319-2003.ijbcp20162893","article-title":"Drug Utilization 90%: an Innovative Method in Assessing Quality of Drug Prescription with Specific Reference to Non-steroidal Anti-inflammatory Drugs Prescription","volume":"5","author":"Dhananjay","year":"2016","journal-title":"Int. J. Basic Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/s0140-6736(03)14286-9","article-title":"Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients with Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"B15","first-page":"1279","article-title":"Managing Hypertension Using Combination Therapy","volume":"77","author":"Frank","year":"2008","journal-title":"Am. Fam. Physician"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, Regional, and National Age-sex-specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980-2017: a Systematic Analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/ijcp.12130","article-title":"Influence of Multiple Initiatives in Sweden to Enhance ARB Prescribing Efficiency Following Generic Losartan; Findings and Implications for Other Countries","volume":"67","author":"Godman","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"B18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3389\/fphar.2014.00106","article-title":"Multiple Policies to Enhance Prescribing Efficiency for Established Medicines in Europe with a Particular Focus on Demand-Side Measures: Findings and Future Implications","volume":"5","author":"Godman","year":"2014","journal-title":"Front. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1741-7015-12-98","article-title":"Can Authorities Appreciably Enhance the Prescribing of Oral Generic Risperidone to Conserve Resources? Findings from across Europe and Their Implications","volume":"12","author":"Godman","year":"2014","journal-title":"BMC Med."},{"key":"B20","volume-title":"Hypertension, Guideline for Clinical Practice","year":"2004"},{"key":"B21","volume-title":"Hypertension, Guideline for Clinical Practice","year":"2009"},{"key":"B22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1742-7843.2011.00682.x","article-title":"The 'wise List'- a Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm","volume":"108","author":"Gustafsson","year":"2011","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s43044-020-00044-6","article-title":"Adherence to Antihypertensive Fixed-Dose Combination Among Egyptian Patients Presenting with Essential Hypertension","volume":"72","author":"Hassanein","year":"2020","journal-title":"Egypt Heart J."},{"key":"B24","volume-title":"The Rights of the Insured","year":"2021"},{"key":"B25","volume-title":"Drug Lists","year":"2021"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril Plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in Hypertensive Patients at High Cardiovascular Risk Treated with Regimens Based on Valsartan or Amlodipine: The VALUE Randomised Trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2147\/CIA.S40154","article-title":"Increasing Complexity: Which Drug Class to Choose for Treatment of Hypertension in the Elderly?","volume":"9","author":"Kaiser","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s11606-020-06103-7","article-title":"Improving Blood Pressure Management in Primary Care Patients with Chronic Kidney Disease: a Systematic Review of Interventions and Implementation Strategies","volume":"35","author":"Kamath","year":"2020","journal-title":"J. Gen. Intern Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.5114\/aoms.2018.77561","article-title":"Effectiveness of Fixed-Dose Combination Therapy in Hypertension: Systematic Review and Meta-Analysis","volume":"14","author":"Kawalec","year":"2018","journal-title":"Arch. Med. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1056\/NEJMe0801709","article-title":"Treating Hypertension in the Very Old","volume":"358","author":"Kostis","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.clinthera.2018.05.018","article-title":"Antihypertensive Drugs in Croatia: What Changes the Drug Usage Patterns?","volume":"40","author":"Kucan","year":"2018","journal-title":"Clin. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/14737167.2018.1501558","article-title":"Ongoing Activities to Optimize the Quality and Efficiency of Lipid-Lowering Agents in the Scottish National Health Service: Influence and Implications","volume":"18","author":"Leporowski","year":"2018","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.medici.2017.07.004","article-title":"Utilization of Cardiovascular Medicines and Cardiovascular Mortality in Lithuania, Sweden and Norway in 2003-2012","volume":"53","author":"Lisauskien\u0117","year":"2017","journal-title":"Med. Kaunas."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"28","author":"Mancia","year":"2007","journal-title":"Eur. Heart J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur. Heart J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/pds.1704","article-title":"Utilisation of Cardiovascular Medicines in Republic of Srpska, Bosnia and Herzegovina, 5 Years Study","volume":"18","author":"Markovic-Pekovic","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B38","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1586\/erp.12.48","article-title":"Ongoing Initiatives in the Republic of Srpska to Enhance Prescribing Efficiency: Influence and Future Directions","volume":"12","author":"Markovic-Pekovic","year":"2012","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1586\/14737167.2016.1115347","article-title":"Polypharmacy Among the Elderly in the Republic of Srpska: Extent and Implications for the Future","volume":"16","author":"Markovi\u0107-Pekovi\u0107","year":"2016","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/jphsr\/rmaa017","article-title":"Compliance to Hypertensive Prescribing Guidelines and Blood Pressure Control in Elderly Patients in Namibia: Findings and Implications","volume":"12","author":"Mashozhera","year":"2021","journal-title":"J. Pharm. Health Serv. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/17512433.2017.1371590","article-title":"Prescription Patterns and Adequacy of Blood Pressure Control Among Adult Hypertensive Patients in Kenya; Findings and Implications","volume":"10","author":"Mbui","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jacc.2018.07.026","article-title":"The Blood Pressure Landscape: Schism Among Guidelines, Confusion Among Physicians, and Anxiety Among Patients","volume":"72","author":"Messerli","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The Global Epidemiology of Hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"B44","volume-title":"Guideline for Clinical Practice: Arterial Hipertension","year":"2015"},{"key":"B45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3389\/fphar.2014.00219","article-title":"Different Initiatives across Europe to Enhance Losartan Utilization Post Generics: Impact and Implications","volume":"5","author":"Moon","year":"2014","journal-title":"Front. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/heartjnl-2018-313492","article-title":"Fixed-dose Combination Antihypertensives and Risk of Medication Errors","volume":"105","author":"Moriarty","year":"2019","journal-title":"Heart"},{"key":"B47","volume-title":"Hypertension: Clinical Management of Primary Hypertension in Adults (NICE Clinical Guideline 127)","year":"2011"},{"key":"B48","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide Trends in Hypertension Prevalence and Progress in Treatment and Control from 1990 to 2019: a Pooled Analysis of 1201 Population-Representative Studies with 104 Million Participants","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/s0140-6736(00)03307-9","article-title":"Effects of ACE Inhibitors, Calcium Antagonists, and Other Blood-Pressure-Lowering Drugs: Results of Prospectively Designed Overviews of Randomised Trials. Blood Pressure Lowering Treatment Trialists' Collaboration","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"key":"B50","volume-title":"Hypertension: Improving Blood Pressure Management in Primary Care","year":"2017"},{"key":"B51","volume-title":"Drug Consumption in Norway 2004\u20132008","year":"2014"},{"key":"B52","volume-title":"National Agency for Medicines F. Drug Consumption Statistics","year":"2014"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of Nine Societies and by Invited Experts)","volume":"33","author":"Perk","year":"2012","journal-title":"Eur. Heart J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e0202250","DOI":"10.1371\/journal.pone.0202250","article-title":"Assessment of Hypertension Chronic Care Model: Pacic Application in Bosnia and Herzegovina","volume":"13","author":"Pilipovic-Broceta","year":"2018","journal-title":"PLoS ONE"},{"key":"B55","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1161\/HYPERTENSIONAHA.118.11452","article-title":"Are the American Heart Association\/American College of Cardiology High Blood Pressure Guidelines Fit for Global Purpose?: Thoughts from the International Society of Hypertension","volume":"72","author":"Poulter","year":"2018","journal-title":"Hypertension"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","article-title":"Health Outcomes Associated with Various Antihypertensive Therapies Used as First-Line Agents: A Network Meta-Analysis","volume":"289","author":"Psaty","year":"2003","journal-title":"JAMA"},{"key":"B57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11906-017-0715-4","article-title":"Ambiguities in the Guidelines for the Management of Arterial Hypertension: Indian Perspective with a Call for Global Harmonization","volume":"19","author":"Rehan","year":"2017","journal-title":"Curr. Hypertens. Rep."},{"key":"B58","volume-title":"Demographic Statistics. Statistical Yearbook 2020","year":"2020"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","article-title":"Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Stanaway","year":"2018","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/j.amjcard.2017.08.042","article-title":"Seventeen-Year Nationwide Trends in Antihypertensive Drug Use in Denmark","volume":"120","author":"Sundb\u00f8ll","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.4103\/1319-2442.270264","article-title":"A Narrative Review of the Impacts of Income, Education, and Ethnicity on Arterial Hypertension, Diabetes Mellitus, and Chronic Kidney Disease in the World","volume":"30","author":"Tirapani","year":"2019","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"B62","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2298\/VSP141119047T","article-title":"Patterns of Prescription Antihypertensive Drug Utilization and Adherence to Treatment Guidelines in the City of Novi Sad","volume":"73","author":"Tomas","year":"2016","journal-title":"Vojnosanit. Pregl."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2020.09.001","article-title":"The 2020 International Society of Hypertension Global Hypertension Practice Guidelines - Key Messages and Clinical Considerations","volume":"82","author":"Verdecchia","year":"2020","journal-title":"Eur. J. Intern Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e1002584","DOI":"10.1371\/journal.pmed.1002584","article-title":"Fixed-dose Combination Antihypertensive Medications, Adherence, and Clinical Outcomes: A Population-Based Retrospective Cohort Study","volume":"15","author":"Verma","year":"2018","journal-title":"PLoS Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1586\/erp.11.42","article-title":"Influence of Demand-Side Measures to Enhance Renin-Angiotensin Prescribing Efficiency in Europe: Implications for the Future","volume":"11","author":"Von\u010dina","year":"2011","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"205","DOI":"10.5937\/siks1303205V","article-title":"Taking Measures of Secondary Prevention of Coronary Heart Disease in Clinical Practice","volume":"32","author":"Vuli\u0107","year":"2013","journal-title":"Srce i krvni sudovi"},{"key":"B68","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2018.10359","article-title":"Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients with Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial","volume":"320","author":"Webster","year":"2018","journal-title":"JAMA"},{"key":"B69","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/08037051.2018.1527177","article-title":"2018 Practice Guidelines for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"27","author":"Williams","year":"2018","journal-title":"Blood Press"},{"key":"B70","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2217\/cer.12.52","article-title":"Ongoing Measures to Enhance the Efficiency of Prescribing of Proton Pump Inhibitors and Statins in The Netherlands: Influence and Future Implications","volume":"1","author":"Woerkom","year":"2012","journal-title":"J. Comp. Eff. Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/01.HYP.0000103630.72812.10","article-title":"Hypertension Treatment and Control in Five European Countries, Canada, and the United States","volume":"43","author":"Wolf-Maier","year":"2004","journal-title":"Hypertension"},{"key":"B72","volume-title":"Hypertension: Key Facts","year":"2021"},{"key":"B73","volume-title":"Guideline for the Pharmacological Treatment of Hypertension in Adults","year":"2021"},{"key":"B74","volume-title":"Introduction to Drug Utilization Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services","year":"2003"},{"key":"B75","volume-title":"European Health for All Database","year":"2019"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and Morbidity Reduction with Candesartan in Patients with Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low-Left Ventricular Ejection Fraction Trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"key":"B77","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJM200001203420301","article-title":"Correction: Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/08037059309077535","article-title":"The 1993 Guidelines for the Management of Mild Hypertension: Memorandum from a WHO\/ISH Meeting","volume":"2","author":"Zanchetti","year":"1993","journal-title":"Blood Press"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","article-title":"2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension","volume":"21","author":"Zanchetti","year":"20032003","journal-title":"J. Hypertens."},{"key":"B80","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5334\/aogh.2591","article-title":"A Global View on Prevalence of Hypertension and Human Develop Index","volume":"86","author":"Zeng","year":"2020","journal-title":"Ann. Glob. Health"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.889047\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T05:51:17Z","timestamp":1655272277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.889047\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":80,"alternative-id":["10.3389\/fphar.2022.889047"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.889047","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"article-number":"889047"}}